Skip to main content
SpringerLink
Log in

ASO Author Reflections: Percutaneous Hepatic Perfusion: Past, Present, and Future

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carvajal RD, Sacco JJ, Jager MJ, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20(2):99–115.

    Article  PubMed  Google Scholar 

  2. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with Tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–206.

    Article  CAS  PubMed  Google Scholar 

  4. Zager JS, Orloff M, Francesco FP, et al. Melphalan/hepatic delivery system for hepatic-dominant ocular melanoma. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15293-x.

    Article  Google Scholar 

  5. Tong TML, Burgmans MC, Speetjens FM, van Erkel AR, van der Meer RW, van Rijswijk CSP, Jonker-Bos MA, Roozen CFM, Sporrel-Blokland M, Lutjeboer J, van Persijn van Meerten EL, van Martini CH, Zoethout RWM, Tijt FGJ, Blank CU, Kapitejin EK. Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the Phase Ib part of the Chopin trial. CardioVasc Intervent Radiol. 2023;46(3):350–9. https://doi.org/10.1007/s00270-022-03338-1.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cutaneous Oncology, Moffit Cancer Center, Tampa, FL, USA

    Jonathan S. Zager MD, FACS, FSSO

  2. Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA

    Jonathan S. Zager MD, FACS, FSSO

Authors
  1. Jonathan S. Zager MD, FACS, FSSO
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan S. Zager MD, FACS, FSSO.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article refers to: Zager JS, Orloff M, Francesco FP, et al. Melphalan/hepatic delivery system for hepatic-dominant ocular melanoma. Annals Surgical Oncology. (2024). https://doi.org/10.1245/s10434-024-15293-x.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zager, J.S. ASO Author Reflections: Percutaneous Hepatic Perfusion: Past, Present, and Future. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15364-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1245/s10434-024-15364-z

Search

Navigation